High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia

Clinical Microbiology and Infection

Volumn 16, Issue 8, 2010, Pages 1191-1196

  Lafaurie, M ^a   Lapalu, J ^a   Raffoux, E ^a   Breton, B ^a   Lacroix, C ^a   Socie G ^a   Porcher, R ^a   Ribaud, P ^a   Touratier, S ^a   Molina, J M ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Aspergillosis; Breakthrough; Caspofungin; Empirical; Neutropenia

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; DEOXYCHOLIC ACID; FLUCONAZOLE; AMPHOTERICIN B, DEOXYCHOLATE DRUG COMBINATION; ANTIFUNGAL AGENT; DRUG COMBINATION; ECHINOCANDIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FALSE POSITIVE RESULT; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; KIDNEY FAILURE; LYMPHOMA; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; COMPLICATION; DRUG COMBINATION; FEVER OF UNKNOWN ORIGIN; IMMUNOCOMPROMISED PATIENT; MICROBIOLOGY; MIDDLE AGED; NEUTROPENIA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; FEVER OF UNKNOWN ORIGIN; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; NEUTROPENIA; YOUNG ADULT;

EID: 77955165880     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.03050.x     Document Type: Article

References (22)

1. Bodey GP. Fungal infection and fever of unknown origin in neutropenic patients. Am J Med 1986, 80:112-119.
2. Fraser IS, Denning DW. Empiric amphotericin B therapy: the need for a reappraisal. Blood Rev 1993, 7:208-214.
3. Aisner J, Wiernik PH, Schimpf SC. Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med 1977, 86:539-543.
4. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982, 72:101-111.
5. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989, 86:668-672.
6. Cagnoni PJ, Walsh TJ, Prendergast MM. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000, 18:2476-2483.
7. Walsh TJ, Teppler H, Donowitz GR. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004, 351:1391-1402.
8. Walsh TJ, Pappas P, Winston DJ. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002, 346:225-234.
9. De Pauw B, Walsh T, Donnelly J. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
10. De Gregorio MW, Lee W, Linker CA. Fungal infections in patients with acute leukaemia. Am J Med 1982, 73:543-548.
11. Wald A, Leisenring W, Van Burik JA. Epidemiology of aspergillosis infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997, 175:1459-1466.
12. Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropenic cancer patients with persistent fever. Guidelines from the first European Conference on Infections in Leukaemia (ECIL). Eur J Cancer 2007, 5:32-42.
13. Walsh TJ, Finberg RW, Arndt C. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999, 340:764-771.
14. Wingard JR, White MH, Anaissie E. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000, 31:1155-1163.
15. Winston DJ, Hathorn JW, Schuster MG. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000, 108:282-289.
16. Boogaerts M, Winston DJ, Bow EJ. Intravenous and oral itraconazole versus intravenous amphotericin B depxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. Ann Intern Med 2001, 135:412-422.
17. Bartizal K, Gill CJ, Abruzzo GK. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997, 41:2326-2332.
18. Madureira A, Bergeron A, Lacroix C. Breathrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007, 30(6):551-554.
19. Maertens J, Raad I, Petrikkos G. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004, 39:1563-1571.
20. Betts R, Glasmacher A, Maertens J. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006, 106:466-473.
21. Viscoli C, Herbrecht R, Akan H. Caspofungin (C) as First-line therapy of invasive aspergillosis (IA) in haematological patients (pts): a study of the EORTC Infectious Diseases Group 2007, Abstract n° O.12, 3rd TIMM, Torino
22. Herbrecht R, Maertens J, Baila L. Caspofungin as first-line therapy of invasive aspergillosis in allogeneic hematopoietic stem cell transplant recipients: a study of the EORTC infectious diseases group 2008, Abstract M-2167. 48th ICAAC, Washington, DC